Prevention of in-stent neointimal proliferation by Pioglitazone Study

Prevention of in-stent neointimal proliferation by Pioglitazone Study - POPPS

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000000485

Enrollment

100

Registered

2006-09-13

Start date

2003-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetic patients with ischemic heart disease

Interventions

Control group: Patients are randomely asseigned to either control or Pioglitazone group. Control group can be treated with any medication except for Pioglitazone. Intervention group: Patients are rand

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Stable angina pectoris or acute coronary syndrome (unstabel angina pectoris or acute myocardial infarction) with type 2 diabetes mellitus diagnosed by the following criteria. (1). FBS >= 126mg/dl (2). Glucose level 2 hours after 75g OGTT >= 200mg/dl (3). Known history of diabetes mellitus

Exclusion criteria

Exclusion criteria: (1).Severe liver or renal insufficiency(2).TIMI-flow grade <= 2 (3).Cardiogenic shock or congestive heart failure (4).Contraindication to antiplatelet therapy (5).Patient with gastrointestinal bleeding or transient ischemic attack (6).Ineligible for CABG (7). Ineligible for percutaneous coronary intervention

Design outcomes

Primary

Measure	Time frame
Angiographical restenosis and target lesion revascularization at 6 months follow-up	—

Secondary

Measure	Time frame
Neointimal volume assessed by intravascular ultrasound at 6months follow-up	—

Countries

Japan

Contacts

Public ContactHiroyuki Okura

Kawasaki Medical School Division of Cardiology

hokura@fides.dti.ne.jp086-462-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026